SCHEMBL6358138

SCHEMBL6358138

CC(=O)N(CC(=O)c1ccccc1)C(C(N)=O)c1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TRPM8 Q7Z2W7 15/20 0.51
NR1I2 O75469 1/20 0.44
KDM4E B2RXH2 3/20 0.44
ALDH1A1 P00352 2/20 0.44
USP2 O75604 1/20 0.44
KMT2A Q03164 2/20 0.42
ATM Q13315 1/20 0.39
MAPT P10636 2/20 0.39
MEN1 O00255 1/20 0.39
CYP3A4 P08684 1/20 0.39
HPGD P15428 1/20 0.39
ALOX15 P16050 1/20 0.39
CES1 P23141 1/20 0.39
MAPK1 P28482 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
AGTR1 P30556 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6350686 0.88 KDM4E (0.46) TRPM8KDM4EALDH1A1USP2KMT2A
SCHEMBL6351176 0.84 TRPM8 (0.44) TRPM8KDM4EALDH1A1USP2KMT2A
SCHEMBL6350920 0.81 ALDH1A1 (0.41) TRPM8KDM4EALDH1A1USP2KMT2A
SCHEMBL6347733 0.81 ALDH1A1 (0.43) TRPM8NR1I2KDM4EALDH1A1USP2
SCHEMBL6347856 0.81 ALDH1A1 (0.43) TRPM8NR1I2KDM4EALDH1A1USP2
SCHEMBL6354208 0.81 ALDH1A1 (0.43) TRPM8NR1I2KDM4EALDH1A1USP2
SCHEMBL6349644 0.80 KDM4E (0.40) TRPM8KDM4EALDH1A1USP2KMT2A
SCHEMBL6349239 0.78 POLB (0.38) TRPM8KDM4EALDH1A1USP2KMT2A
SCHEMBL6347134 0.77 TRPM8 (0.44) TRPM8NR1I2KDM4EALDH1A1USP2
SCHEMBL6345185 0.77 KDM4E (0.45) KDM4EALDH1A1USP2KMT2AATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6960575-B2 For use as inhibitors of chymase SANTEN PHARMACEUTICAL CO., LTD. (JP) 2005-11-01 US disclosed
US-20040097496-A1 Novel thiazine derivatives SANTEN PHARMACEUTICAL CO.,LTD. (JP) 2004-05-20 US disclosed
US-6713472-B1 2-OXO-1,2,3,4-TETRAHYDROPYRAZINE DERIVATIVES; CHYMASE INHIBITORS SANTEN PHARMACEUTICAL CO., LTD. (JP) 2004-03-30 US disclosed
EP-1211249-A1 NOVEL THIAZINE OR PYRAZINE DERIVATIVES SANTEN PHARMACEUTICAL CO., LTD. (JP) 2002-06-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040097496-A1 Novel thiazine derivatives CMA1, TPSD1, HRH4 TRPM8 1934/4885NR1I2 426/4885KDM4E 2934/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.